INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY

This clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. P. Pyltsin, E. Yu. Zlatnik, Yu. N. Lazutin, G. Z. Sergostyants, G. I. Zakora, I. A. Leyman, P. A. Anistratov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2015
Materias:	lung adenocarcinoma adjuvant chemotherapy chemoimmunotherapy interferon-gamma Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/1ff2316bfccd431f94678092ea31bdf8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1ff2316bfccd431f94678092ea31bdf8
record_format	dspace
spelling	oai:doaj.org-article:1ff2316bfccd431f94678092ea31bdf82021-11-18T08:03:44ZINFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY1563-06252313-741X10.15789/1563-0625-2014-6-559-566https://doaj.org/article/1ff2316bfccd431f94678092ea31bdf82015-01-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/768https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThis clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group received adjuvant chemoimmunotherapy accomplished with Ingaron, whereas 30 cases (48%) in control group were assigned to receive conventional adjuvant chemotherapy. Adjuvant chemoimmunotherapy was administered according to the following schedule: carboplatinum, AUC = 5 i.v. on day 1; etoposide, 100 mg/m2 i.v. on days 1,3,5; interferon-gamma, 500.000 I.E./m2 i.v. on days 2,4,6. In the patiens undergoing lobectomy, carboplatinum was replaced for cisplatinum 100 mg/m2 i.v. on day 1. Comparative evaluation of the both treatment regimens has shown a correcting effect of Ingaron upon cellular immunity links. The Ingaroncontaining chemoimmunotherapy may contribute to improvement of 3-year event-free survival among lung adenocarcinoma patients by 19 percent (p = 0.06607).S. P. PyltsinE. Yu. ZlatnikYu. N. LazutinG. Z. SergostyantsG. I. ZakoraI. A. LeymanP. A. AnistratovSPb RAACIarticlelung adenocarcinomaadjuvant chemotherapychemoimmunotherapyinterferon-gammaImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 16, Iss 6, Pp 559-566 (2015)
institution	DOAJ
collection	DOAJ
language	RU
topic	lung adenocarcinoma adjuvant chemotherapy chemoimmunotherapy interferon-gamma Immunologic diseases. Allergy RC581-607
spellingShingle	lung adenocarcinoma adjuvant chemotherapy chemoimmunotherapy interferon-gamma Immunologic diseases. Allergy RC581-607 S. P. Pyltsin E. Yu. Zlatnik Yu. N. Lazutin G. Z. Sergostyants G. I. Zakora I. A. Leyman P. A. Anistratov INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
description	This clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group received adjuvant chemoimmunotherapy accomplished with Ingaron, whereas 30 cases (48%) in control group were assigned to receive conventional adjuvant chemotherapy. Adjuvant chemoimmunotherapy was administered according to the following schedule: carboplatinum, AUC = 5 i.v. on day 1; etoposide, 100 mg/m2 i.v. on days 1,3,5; interferon-gamma, 500.000 I.E./m2 i.v. on days 2,4,6. In the patiens undergoing lobectomy, carboplatinum was replaced for cisplatinum 100 mg/m2 i.v. on day 1. Comparative evaluation of the both treatment regimens has shown a correcting effect of Ingaron upon cellular immunity links. The Ingaroncontaining chemoimmunotherapy may contribute to improvement of 3-year event-free survival among lung adenocarcinoma patients by 19 percent (p = 0.06607).
format	article
author	S. P. Pyltsin E. Yu. Zlatnik Yu. N. Lazutin G. Z. Sergostyants G. I. Zakora I. A. Leyman P. A. Anistratov
author_facet	S. P. Pyltsin E. Yu. Zlatnik Yu. N. Lazutin G. Z. Sergostyants G. I. Zakora I. A. Leyman P. A. Anistratov
author_sort	S. P. Pyltsin
title	INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
title_short	INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
title_full	INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
title_fullStr	INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
title_full_unstemmed	INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
title_sort	influence of ingaron upon immune state of the patients with adenocarcinoma of lung in the course of adjuvant therapy
publisher	SPb RAACI
publishDate	2015
url	https://doaj.org/article/1ff2316bfccd431f94678092ea31bdf8
work_keys_str_mv	AT sppyltsin influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT eyuzlatnik influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT yunlazutin influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT gzsergostyants influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT gizakora influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT ialeyman influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT paanistratov influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy
_version_	1718422401213005824

INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY

Ejemplares similares